Senti Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | ||||
| Contract revenue | $— | $255 | $— | $1,978 |
| Grant income | — | 83 | — | 583 |
| Total revenue | — | 338 | — | 2,561 |
| Operating expenses | ||||
| Research and development (including related party cost of $3,790 and $1,186 for the three months ended September 30, 2024 and 2023, respectively, and $11,059 and $1,186 for the nine months ended September 30, 2024 and 2023, respectively) | 8,655 | 9,092 | 26,584 | 23,028 |
| General and administrative | 6,247 | 9,431 | 17,975 | 27,871 |
| Impairment of long-lived assets | 313 | 25,691 | 313 | 25,691 |
| Total operating expenses | 15,215 | 44,214 | 44,872 | 76,590 |
| Loss from operations | (15,215) | (43,876) | (44,872) | (74,029) |
| Other income (expense) | ||||
| Interest income, net | 150 | 583 | 718 | 2,438 |
| Change in fair value of contingent earnout liability | — | — | — | 207 |
| Change in fair value of GeneFab Note Receivable - related party | (17,435) | 287 | (17,240) | 287 |
| Change in fair value of GeneFab Economic Share - related party | (398) | (123) | (1,816) | (123) |
| Change in fair value of GeneFab Option - related party | 2,386 | 5,629 | 6,331 | 5,629 |
| GeneFab sublease income - related party | 1,657 | 899 | 4,705 | 899 |
| Other income (expense) | (11) | (14) | (6) | (26) |
| Total other income (expense), net | (13,651) | 7,261 | (7,308) | 9,311 |
| Net loss from continuing operations | (28,866) | (36,615) | (52,180) | (64,718) |
| Net income from discontinued operations | — | 21,692 | — | 12,376 |
| Net loss | (28,866) | (14,923) | (52,180) | (52,342) |
| Other comprehensive loss | ||||
| Unrealized loss on investments | — | — | — | (1) |
| Comprehensive loss | $(28,866) | $(14,923) | $(52,180) | $(52,343) |
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net loss per share, basic and diluted | ||||
| Net loss per share from continuing operations, basic and diluted | $(6.31) | $(8.24) | $(11.41) | $(14.62) |
| Net income per share from discontinued operations, basic and diluted | — | 4.88 | — | 2.80 |
| Net loss per share, basic and diluted | $(6.31) | $(3.36) | $(11.41) | $(11.82) |
| Weighted-average shares outstanding, basic and diluted | 4,577,122 | 4,447,223 | 4,573,307 | 4,427,458 |
All periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on July 17, 2024. Refer to Note 2. Summary of Significant Accounting Policies, for further information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.